Gerald Willimsky

9PUBLICATIONS
57CO-AUTHORS
Molecular targetsMedical mycologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jul 15, 2026
Oncogene inactivation-induced senescence facilitates tumor relapse.

|Jun 03, 2025
Enhanced mutanome analysis towards the induction of neoepitope-reactive T-cell responses for personalized immunotherapy of pancreatic cancer.

|May 02, 2025
Selection of therapeutically effective T-cell receptors from the diverse tumor-bearing repertoire.

Leonie Rosenberger, Leo Hansmann, Vasiliki Anastasopoulou

|Feb 07, 2025
Bone marrow breakout lesions act as key sites for tumor-immune cell diversification in multiple myeloma.

Raphael Lutz, Alexandra M Poos, Llorenç Solé-Boldo

|Mar 14, 2023
Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda et al.

Lena Immisch, George Papafotiou, Oliver Popp

|Oct 27, 2022
H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma.

Lena Immisch, George Papafotiou, Oliver Popp

Pageof 2

Frequent Collaborators

2 joint publications

Simon Haas

1 joint publications

Andrean Goede

1 joint publications

Michael Kilian

1 joint publications

Stefan Pusch